<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993366</url>
  </required_header>
  <id_info>
    <org_study_id>2019-4947</org_study_id>
    <nct_id>NCT03993366</nct_id>
  </id_info>
  <brief_title>Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement</brief_title>
  <official_title>A Preliminary Pilot Study to Assess Insulin-plus-Pramlintide Closed-loop Delivery System in Pump Treated Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to generate preliminary data of (i) Fiasp-plus-Pramlintide
      closed-loop system with a simple meal announcement, compared to (ii) Fiasp-alone closed-loop
      system with full carbohydrate counting, in preparation for an outpatient study over two weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is a randomized, 2-way, crossover trial assessing:
i. Fiasp-alone closed-loop system with full carbohydrate counting ii. Fiasp-plus-Pramlintide closed-loop system with simple meal announcement in regulating glucose levels in patients with type 1 diabetes, over a period of 24h in an inpatient setting.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in target</measure>
    <time_frame>24 hours</time_frame>
    <description>Time spent in target range (between 4.0 mmol/L and 10 mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time in hypoglycemia</measure>
    <time_frame>24 hours</time_frame>
    <description>Time spent in hypoglycemic range (below 4.0 mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time in hyperglycemia</measure>
    <time_frame>24 hours</time_frame>
    <description>Time spent in hyperglycemic range (above 10.0 mmol/L)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Hypoglycemia treatment</measure>
    <time_frame>24 hrs</time_frame>
    <description>Number of participants experiencing hypoglycemia requiring oral treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia treatment</measure>
    <time_frame>During the night of the 24 hour intervention (11pm-7am)</time_frame>
    <description>Number of participants experiencing hypoglycemia requiring oral treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia treatment</measure>
    <time_frame>During the day of the 24 hour intervention (7am-11pm)</time_frame>
    <description>Number of participants experiencing hypoglycemia requiring oral treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>24 hours</time_frame>
    <description>Presence of gastrointestinal symptoms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Simple Meal Announcement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before every meal, the meal will be simply announced to the algorithm by a member of the study team. Meal bolus computation will be independent of the carbohydrate content of the meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full Carbohydrate counting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The carbohydrate content of the meal selected by the participant will be entered into the dosing algorithm by a member of the study team at the onset of the meal to compute the insulin prandial bolus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Fiasp+Pramlintide Closed-Loop System</intervention_name>
    <description>Closed-loop insulin delivery with Fiasp insulin and pramlintide</description>
    <arm_group_label>Simple Meal Announcement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fiasp Closed-Loop System</intervention_name>
    <description>Closed-loop insulin delivery with Fiasp insulin alone</description>
    <arm_group_label>Full Carbohydrate counting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ≥ 12 years of age.

          2. Clinical diagnosis of type 1 diabetes for at least 12 months according to the Diabetes
             Canada Clinical Practice Guidelines Expert Committee diagnostic criteria.

          3. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide
             level and antibody determinations are not needed.

          4. Insulin pump therapy for at least 6 months.

          5. HbA1c ≤ 12%.

        Exclusion Criteria:

          1. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2 (Sodium-glucose
             Cotransporter-2), GLP-1 (glucagon-like peptide 1), Metformin, Acarbose, etc.…).

          2. Current use of glucocorticoid medication.

          3. Use of medication that alters gastrointestinal motility.

          4. Planned or ongoing pregnancy.

          5. Breastfeeding individuals.

          6. Severe hypoglycemic episode within one month of admission.

          7. Severe diabetes keto-acidosis episode within one month of admission.

          8. Clinically significant nephropathy, neuropathy or retinopathy as judged by the
             investigator.

          9. Recent (&lt; 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac
             surgery.

         10. Known hypersensitivity to any of the study drugs or their excipients.

         11. Individuals with hypoglycemia unawareness.

         12. Individuals with confirmed gastroparesis.

         13. Other serious medical illness likely to interfere with study participation or with the
             ability to complete the trial by the judgment of the investigator.

         14. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks,
             not willing to change pump parameters, etc.).

        Study Discontinuation/Withdrawal

          1. Failure to comply with the protocol.

          2. Pregnancy.

          3. After an event which the PI believes it is not in the best interest for the patient to
             continue the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer René</last_name>
    <phone>‭(418) 558-0742‬</phone>
    <email>jennifer.rene@mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer René</last_name>
      <phone>‭(418) 558-0742‬</phone>
      <email>jennifer.rene@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Tsoukas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmad Haidar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Legault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Von Oettinge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Francois Yale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>pramlintide</keyword>
  <keyword>closed-loop</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

